AWA
CRSP icon

Arkadios Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Arkadios Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Hold
200
– – ﹤0.01% 1753
2026
Q1 		$9.51K Hold
200
– – ﹤0.01% 1683
2025
Q4 		$10.5K Hold
200
– – ﹤0.01% 1559
2025
Q3 		$13K Sell
200
-700
-78% -$40.2K ﹤0.01% 1462
2025
Q2 		$43.8K Buy
+900
New +$34.8K ﹤0.01% 1292

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arkadios Wealth Advisors's CRSP Position: Q2 2026 in Review

Arkadios Wealth Advisors increased its CRISPR Therapeutics (CRSP) stake by 11% in Q2 2026, buying an estimated $56.5K and bringing the position to 10,487 shares worth $572K. The position accounts for 0.01% of the portfolio, ranked #1064.

Arkadios Wealth Advisors first reported a position in CRSP in Q1 2020 and has held it in 25 quarters since. The position peaked at $971K in Q4 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Arkadios Wealth Advisors held 10,487 shares of CRISPR Therapeutics worth $572K as of Q2 2026.
  • Arkadios Wealth Advisors bought 1,071 CRISPR Therapeutics shares in Q2 2026, an estimated $56.5K.
  • CRISPR Therapeutics made up 0.01% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #1064 holding.
  • Arkadios Wealth Advisors first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Arkadios Wealth Advisors's CRISPR Therapeutics position peaked at $971K in Q4 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.